Evidence map›Paper›PMID 41026084›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

Farnesiferol C enhances the effects of chemotherapy and ionising radiation in human melanoma cells via targeting topoisomerase II alpha.

Negin Moosavinejad, Zahra Nasiri Sarvi, Hamid Gholamhosseinian, Mehrdad Iranshahi, Fatemeh B Rassouli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Negin MoosavinejadNovel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
Zahra Nasiri SarviNovel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
Hamid GholamhosseinianDepartment of Medical Physics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mehrdad IranshahiBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Fatemeh B RassouliNovel Diagnostics and Therapeutics Research Group, Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study evaluated Farnesiferol C (FC), a natural coumarin, as a potential topoisomerase IIα (TOP2A) inhibitor to enhance chemotherapy and ionising radiation (IR) efficacy in melanoma cells. Key targets were identified, followed by enrichment and gene expression analyses, and molecular docking and dynamics simulations. Upon extraction of FC from

Indexed as

Antineoplastic AgentsDNA Topoisomerases, Type IIMelanomaPoly-ADP-Ribose Binding ProteinsTopoisomerase II InhibitorsApoptosisCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular Docking SimulationMolecular StructureRadiation, IonizingStructure-Activity RelationshipAntineoplastic AgentsDNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsTemozolomideTOP2A protein, humanTopoisomerase II Inhibitorschemotherapyfarnesiferol Cionising radiationMelanomatopoisomerase II alpha

Identifiers

PMID41026084
PMCPMC12486455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.